hI Werds,
the current short term FDA opportunity is worth circa NZD$25- 27 million in sales (1 million tins) and $5-6 million in profit( less any extra over overheads). Not a game changer by any means.
the big kicker is if FDA grants permanent access and A2 would be able to sell IF ongoing, you could see this growing to 5 million tins a year business i.e NZD$125-150 million sales and $25-30 million in profit.
Ann: Deferral of FDA consideration of enforcement discretion, page-100
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.01 |
Change
-0.320(4.37%) |
Mkt cap ! $5.067B | |||
| Open | High | Low | Value | Volume |
| $7.30 | $7.31 | $6.97 | $21.32M | 3.015M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 16013 | $6.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.02 | 8673 | 3 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$6.98 |
Change
-0.320 ( 4.89 %) |
||||
| Open | High | Low | Volume | ||
| $7.30 | $7.31 | $6.98 | 1538083 | ||
| Last updated 15.59pm 29/05/2024 ? | |||||
| A2M (ASX) Chart |